{"disease":{"id":"cancer-ovary","name":"cancer ovary"},"drugs":{"marketed":[{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":7,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02997553","title":"Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":744,"lead_sponsor_name":"Institut de Cancérologie de Lorraine","has_results":false},{"nct_id":"NCT04000880","title":"Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":603,"lead_sponsor_name":"University of Alabama at Birmingham","has_results":false},{"nct_id":"NCT06969833","title":"Prospective Clinico-biological Database of Patients With Ovarian and/or Peritoneal and/or Fallopian Tube Carcinoma","phase":"NA","overall_status":"RECRUITING","enrollment_count":371,"lead_sponsor_name":"Centre Oscar Lambret","has_results":false},{"nct_id":"NCT04438564","title":"Immunoassay and Regulation of Traditional Chinese Medicine on Cancer Patients","phase":"NA","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"China Medical University Hospital","has_results":false},{"nct_id":"NCT05796973","title":"Measuring Oncological Value of Exercise and Statin","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Tampere University Hospital","has_results":false},{"nct_id":"NCT05677048","title":"Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":205,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04817449","title":"Spectroscopy in Ovarian Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":160,"lead_sponsor_name":"University of Exeter","has_results":false},{"nct_id":"NCT03593681","title":"Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy","phase":"","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Boston Scientific Corporation","has_results":true},{"nct_id":"NCT05059782","title":"Efficacy and Safety of Involving Field Radiotherapy in the Oligo-lesions(Metastasis/Recurrent/Refractory) of Ovarian Cancer","phase":"NA","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"Xi'an Jiaotong University","has_results":false},{"nct_id":"NCT04205227","title":"ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":137,"lead_sponsor_name":"ENB Therapeutics, Inc","has_results":false},{"nct_id":"NCT03748186","title":"Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":136,"lead_sponsor_name":"Sutro Biopharma, Inc.","has_results":false},{"nct_id":"NCT03371693","title":"Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":112,"lead_sponsor_name":"Zhongnan Hospital","has_results":false},{"nct_id":"NCT05187338","title":"Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Second Affiliated Hospital of Guangzhou Medical University","has_results":false},{"nct_id":"NCT03275194","title":"HIPEC in Ovarian Carcinoma Clinical Stage IIIC and IV During Interval Laparotomy","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Instituto Nacional de Cancerologia de Mexico","has_results":false},{"nct_id":"NCT02063464","title":"Blood Collection From People With Ovarian Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":85,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05252390","title":"NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":82,"lead_sponsor_name":"Nuvation Bio Inc.","has_results":false},{"nct_id":"NCT06161272","title":"Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"Guangxi Medical University","has_results":false},{"nct_id":"NCT05080556","title":"Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT05001282","title":"A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":79,"lead_sponsor_name":"Elucida Oncology","has_results":false},{"nct_id":"NCT05246462","title":"The Effect of Logotherapy on Mental Health in Gynecological Cancer Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"Akdeniz University","has_results":false},{"nct_id":"NCT06662435","title":"GYNecologic Cancer-Related COGnitive Impairment","phase":"NA","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Northwestern University","has_results":false},{"nct_id":"NCT05721976","title":"With Love, Grandma (\"Con Cariño, Abuelita\") Pilot Study","phase":"NA","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"University of Miami Sylvester Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT05446298","title":"ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":58,"lead_sponsor_name":"OncoC4, Inc.","has_results":false},{"nct_id":"NCT05200364","title":"A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":58,"lead_sponsor_name":"Sutro Biopharma, Inc.","has_results":false},{"nct_id":"NCT06161233","title":"Pilot Study of the eHealth Application \"Cancer Patients Better Life Experience\" (CAPABLE) - Italy","phase":"NA","overall_status":"COMPLETED","enrollment_count":56,"lead_sponsor_name":"Istituti Clinici Scientifici Maugeri SpA","has_results":false},{"nct_id":"NCT06063070","title":"First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":44,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT03384511","title":"The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"Shandong Cancer Hospital and Institute","has_results":false},{"nct_id":"NCT05429970","title":"A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)","phase":"NA","overall_status":"RECRUITING","enrollment_count":35,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT06964009","title":"DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Elizabeth Stover, MD, PhD","has_results":false},{"nct_id":"NCT04898842","title":"Feasibility Study of a 4 Stage Bowel Obstruction Cancer Diet","phase":"NA","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Royal Surrey County Hospital NHS Foundation Trust","has_results":false},{"nct_id":"NCT02432378","title":"Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":25,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false},{"nct_id":"NCT03199586","title":"Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":23,"lead_sponsor_name":"Novita Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT07168083","title":"Efficacy and Safety of Sacituzumab in Patients With OCCC After Immunotherapy Progression","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":22,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT06478862","title":"Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":19,"lead_sponsor_name":"Lipomedix Pharmaceuticals Inc.","has_results":false},{"nct_id":"NCT05858736","title":"Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":18,"lead_sponsor_name":"OncoC4, Inc.","has_results":false},{"nct_id":"NCT06321484","title":"Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT03133286","title":"Radiotherapy Assessments During Intervention ANd Treatment (RADIANT)","phase":"","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"DxTerity Diagnostics","has_results":false},{"nct_id":"NCT04814875","title":"A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":16,"lead_sponsor_name":"THERAPIM PTY LTD","has_results":false},{"nct_id":"NCT05500508","title":"Oral AMXT 1501 Dicaprate in Combination With IV DFMO","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":15,"lead_sponsor_name":"Aminex Therapeutics, Inc.","has_results":false},{"nct_id":"NCT05538624","title":"A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":14,"lead_sponsor_name":"Avenge Bio, Inc","has_results":false},{"nct_id":"NCT05335993","title":"A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":10,"lead_sponsor_name":"CanariaBio Inc.","has_results":false},{"nct_id":"NCT02582931","title":"MRI-Guided Stereotactic Body Radiation Therapy (SBRT) for Ovarian Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT03162562","title":"The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":10,"lead_sponsor_name":"CanariaBio Inc.","has_results":false},{"nct_id":"NCT05194735","title":"Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":8,"lead_sponsor_name":"Alaunos Therapeutics","has_results":true},{"nct_id":"NCT05292859","title":"Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs","phase":"","overall_status":"COMPLETED","enrollment_count":7,"lead_sponsor_name":"Alaunos Therapeutics","has_results":false},{"nct_id":"NCT03312114","title":"Anti-PD-L1 and SAbR for Ovarian Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":true},{"nct_id":"NCT02669914","title":"MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"Washington University School of Medicine","has_results":true},{"nct_id":"NCT05296564","title":"Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":3,"lead_sponsor_name":"Hadassah Medical Organization","has_results":false},{"nct_id":"NCT04826029","title":"Impact of Systematic Imaging for Follow up of Patients With Ovarian, Fallopian Tube or Primary Peritoneum Cancer","phase":"NA","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false}],"total":49},"guidelines":[],"source":"Drug Landscape verified database"}